Publications by authors named "Andrew Viet"

Claim this Profile
D
Discovery and Optimization of Aryl Piperidinone Ureas as Selective Formyl Peptide Receptor 2 Agonists.
Nicholas R Wurtz, Pravin S Shirude, Daniel L Cheney, John A Lupisella, Amit Kumar Chattopadhyay, Andrew Viet

ACS Med Chem Lett· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists.
Nicholas R Wurtz, James A Johnson, Andrew Viet, Pravin S Shirude, Vishweshwaraiah Baligar

ACS Med Chem Lett· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase.
Scott A Shaw, Benjamin P Vokits, Andrew K Dilger, Andrew Viet, Charles G Clark

Bioorg Med Chem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent Triazolopyridine Myeloperoxidase Inhibitors.
Nicholas R Wurtz, Andrew Viet, Scott A Shaw, Andrew Dilger, Meriah N Valente

ACS Med Chem Lett· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triazolopyrimidines identified as reversible myeloperoxidase inhibitors.
Franck Duclos, Lynn M Abell, David G Harden, Kristen Pike, Kimberly Nowak, Andrew Viet

Medchemcomm· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.
Gren Z Wang, Pamela A Haile, Tom Daniel, Benjamin Belot, Andrew Q Viet

Bioorg Med Chem Lett· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.
Clark A Sehon, Gren Z Wang, Andrew Q Viet, Krista B Goodman, Sarah E Dowdell

J Med Chem· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aminomethylpiperazines as selective urotensin antagonists.
Mark A Hilfiker, Daohua Zhang, Sarah E Dowdell, Krista B Goodman, John J McAtee, Andrew Q Viet

Bioorg Med Chem Lett· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.
John J McAtee, Jason W Dodson, Sarah E Dowdell, Karl Erhard, Gerald R Girard, Andrew Q Viet

Bioorg Med Chem Lett· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of potent and selective small-molecule human Urotensin-II antagonists.
John J McAtee, Jason W Dodson, Sarah E Dowdell, Gerald R Girard, Krista B Goodman, Andrew Q Viet

Bioorg Med Chem Lett· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.
Robert A Stavenger, Haifeng Cui, Sarah E Dowdell, Robert G Franz, Dimitri E Gaitanopoulos, Andrew Q Viet

J Med Chem· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.
Krista B Goodman, Haifeng Cui, Sarah E Dowdell, Dimitri E Gaitanopoulos, Robert L Ivy, Andrew Q Viet

J Med Chem· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis